The FDA approval of the ACTPen was supported by data from 2 studies: an open-label, randomized, 2-period, crossover Phase 1 study (N=188), and an open-label, non-randomized, observational Phase 4 ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved ACTPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of adult ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
Actemra (tocilizumab) is a prescription drug that’s used to treat certain conditions that affect your immune system. Actemra can cause side effects that range from mild to serious. Examples include ...
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
As with other drugs, Actemra can cause side effects, such as weight gain, headache, and injection site reactions. Actemra has a boxed waring about the risk of serious infections. Be sure to talk with ...
Actemra (tocilizumab) is a prescription drug that’s used for arthritis and other conditions. The drug is given as an injection under the skin or an intravenous (IV) infusion. Actemra’s dosage depends ...
March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results